{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"data_sharing_plan":["IPD Sharing (as of May 2020): Undecided"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2242650"],"location":["Taiwan"],"study_start_month":["4"],"keyword":["GI toxicity","Silymarin","CPT-11(irinotecan)"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment","description":"Primary objectives: Use both listed and relatively safe drug, Silymarin,s to improve the intestinal side effect of the patients undergoing FOLFIRI chemotherapy.","dates":{"creation":"2016-04-15"},"accession":"2242650","cross_references":{"ClinicalTrials___gov":["NCT03130634"]}}